SCHEMBL5754936

SCHEMBL5754936

CCOC(=O)N1CCN(c2ccc(C=O)c(Cl)c2)CC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.74
HTT P42858 2/20 0.74
MAPK1 P28482 1/20 0.74
LMNA P02545 3/20 0.58
GAA P10253 2/20 0.58
KDM4E B2RXH2 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.55
ALDH1A1 P00352 7/20 0.52
PDE3B Q13370 1/20 0.52
PDE3A Q14432 1/20 0.52
HPGD P15428 2/20 0.50
GFER P55789 1/20 0.49
PDK2 Q15119 1/20 0.48
KMT2A Q03164 3/20 0.48
TSHR P16473 1/20 0.48
CASP1 P29466 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RAB9A P51151 1/20 0.48
IDE P14735 1/20 0.47
MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28868212 0.86 MAPT (0.63) MAPTHTTMAPK1LMNAGAA
SCHEMBL4937996 0.84 MAPT (0.54) MAPTHTTMAPK1LMNASMN1; SMN2
SCHEMBL11529886 0.80 MAPT (0.74) MAPTHTTMAPK1LMNAGAA
SCHEMBL9694313 0.79 MAPT (0.63) MAPTHTTMAPK1LMNAGAA
SCHEMBL10366199 0.79 MAPT (0.71) MAPTHTTMAPK1LMNAGAA
SCHEMBL844545 0.79 BCL2A1 (0.49) MAPTHTTMAPK1GAAKDM4E
SCHEMBL15127501 0.75 MAPT (0.79) MAPTHTTMAPK1LMNAGAA
SCHEMBL11211555 0.75 MAPT (0.69) MAPTHTTMAPK1LMNAGAA
SCHEMBL29522774 0.75 MAPT (0.69) MAPTHTTMAPK1LMNAGAA
SCHEMBL15093843 0.75 ALDH1A1 (0.59) MAPTLMNAKDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379234-B1 HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF NOVARTIS AG (CH) 2006-03-29 EP disclosed
US-6919336-B2 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of IL-1 and TNF NOVARTIS AG (CH) 2005-07-19 US disclosed
US-20040097731-A1 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf NOVARTIS AG (CH) 2004-05-20 US disclosed
EP-1379234-A1 HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF Novartis AG (CH) 2004-01-14 EP disclosed
WO-2002076447-A1 HALLOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF NOVARTIS AG (CH) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097731-A1 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf TNF, NFKBIA, IL1A MAPT 2379/4885HTT 1136/4885MAPK1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.